



Sensorion to Present Data from Phase 1b Clinical Trial of SENS-111 at AAO-HNSF Annual Meeting

Data Support Further Development of Innovative Treatment for Acute Peripheral Vertigo

Montpellier, May 12, 2016 (FR0012596468 – ALSEN) – Sensorion, a biotech company specializing in the treatment of inner ear diseases, announced today that safety and pharmacokinetic data from its Phase 1b clinical trial of SENS-111 has been accepted for poster presentation at the American Academy of Otolaryngology-Head and Neck Surgery Foundation's 2016 Annual Meeting & OTO EXPO to take place in San Diego, CA September 18-21, 2016.

Poster title: SENS-111, H4 Antagonist for Treatment of Peripheral Vertigo, Is Safe

Poster number and presentation location will be communicated later by the organizers of the scientific conference.

Pierre Attali, Sensorion's Chief Medical Officer, says: *"We are pleased to have clinical data of SENS-111 accepted for presentation at the AAO-HNSF annual meeting. We believe this demonstrates the need recognized by researchers and physicians in the field of otology for an oral treatment for acute vertigo that is safe and effective. With SENS-111, as well as with our pipeline of first-in-class small molecule oral products, we strive to provide patients with an improved and convenient treatment option for inner ear diseases. We look forward to presenting this poster at the upcoming conference and highlighting the potential of our products in this large global market."*

•••

About SENS-111

SENS-111 is the first representative of the histamine type 4 receptor antagonist class tested in inner-ear pathologies. This drug candidate displays a neuromodulation effect of the neurosensorial inner ear cell function and is being developed for the symptomatic treatment of bouts of vertigo or tinnitus. SENS-111 is a small molecule that can be taken orally or via a standard injection, and has been successfully assessed in humans in phase 1b.

About Sensorion

Sensorion specializes in the treatment of pathologies of the inner ear such as acute vertigo, tinnitus and hearing loss. The company was founded by Inserm (the French Institute of Health and Medical Research) and is utilizing its pharmaceutical R&D experience and comprehensive technology platform to develop first-in-class easy-to-administer, notably orally active, drug candidate programs for treating hearing loss and the symptoms of vertigo and tinnitus, for preventing and treating complications associated with progressive lesions in the inner ear, and for preventing the toxicity of chemotherapy in the inner ear. Based in Montpellier, southern France, Sensorion received financial support from Bpifrance, through the InnoBio fund, and Inserm Transfert Initiative.

Sensorion is listed on Alternext Paris since April 2015. www.sensorion-pharma.com

Contacts

Sensorion

Laurent Nguyen

CEO

contact@sensorion-pharma.com

Tel: +33 (0)4 67 20 77 30

Name: **SENSORION**

ISIN code: **FR0012596468**

Ticker: **ALSEN**

International Investor Relations

NewCap

Dusan Oresansky / Emmanuel Huynh

sensorion@newcap.eu

Tel: +33 (0)1 44 71 94 92

US Investor Relations

The Ruth Group

David Burke/Tram Bui

dburke@theruthgroup.com/tbui@theruthgroup.com

Tel: (646) 536-7009/7035



Disclaimer

This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward-looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the prospectus on which the French Financial Market Authority (AMF) granted its visa n° 15-114 on March 27, 2015 and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.